Skip to main content

Leadership

News Release

Printer Friendly Version View printer-friendly version
<< Back
Emergent BioSolutions to Release Second Quarter 2007 Financial Results on August 6, 2007; Management Will Conduct a Conference Call to Discuss Results as Well as Provide an Update on Business Developments
ROCKVILLE, Md., Jul 20, 2007 (BUSINESS WIRE) -- Emergent BioSolutions Inc. (NYSE:EBS), a biopharmaceutical company focused on developing, manufacturing and commercializing immunobiotics to prevent or treat disease, announced today that it will report financial results for the second quarter 2007 on Monday, August 6, 2007, at market close.

Company management will host a conference call at 5:00 pm Eastern on August 6, 2007 to discuss these financial results and to provide an update on business developments, including the status of the BioThrax procurement contract negotiations with HHS and DoD.

Interested parties may participate in the live teleconference by dialing 800/299-7928 or 617/614-3926 or via a webcast which will be accessible on the company's website, www.emergentbiosolutions.com, under "Investors". A replay of the teleconference will be available on the company website or by dialing 888/286-8010 or 617/801-6888 and using the passcode 25894369, approximately one hour after the teleconference concludes. The replay will be available through August 20.

The conference call, replay and webcast are open to all interested parties.

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is a biopharmaceutical company dedicated to one simple mission--to protect life. We develop, manufacture and commercialize immunobiotics, consisting of vaccines and therapeutics that assist the body's immune system to prevent or treat disease. Our biodefense business focuses on immunobiotics for use against biological agents that are potential weapons of bioterrorism and biowarfare. Our marketed product, BioThrax(R) (Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax infection. Our commercial business focuses on immunobiotics for use against infectious diseases and other medical conditions that have resulted in significant unmet or underserved public health needs. More information on the company, its pipeline and activities is available at www.emergentbiosolutions.com.

SOURCE: Emergent BioSolutions Inc.

Investors Contact:
Robert G. Burrows
Vice President, Investor Relations
Emergent BioSolutions Inc.
301-795-1877
burrowsr@ebsi.com